0001415889-24-003891.txt : 20240215 0001415889-24-003891.hdr.sgml : 20240215 20240215160555 ACCESSION NUMBER: 0001415889-24-003891 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jimenez Freddy A. CENTRAL INDEX KEY: 0001838114 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 24643802 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-02152024_090240.xml X0508 4 2024-02-13 0000744218 Celldex Therapeutics, Inc. CLDX 0001838114 Jimenez Freddy A. C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP & GENERAL COUNSEL 0 Common Stock 2024-02-13 4 M 0 4166 9.0165 A 5924 D Common Stock 2024-02-13 4 M 0 20000 2.78 A 25924 D Incentive Stock Option (Right to Buy) 9.0165 2024-02-13 4 M 0 4166 0 D 2028-06-13 Common Stock 4166 0 D Incentive Stock Option (Right to Buy) 2.78 2024-02-13 4 M 0 20000 0 D 2029-06-19 Common Stock 20000 0 D On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. As of June 13, 2022, the option is fully vested. As of June 19, 2023, the option is fully vested. /s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez 2024-02-15